# US 2016/0237420 A1 · Lyophilized formulations for factor xa antidote

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0237420 A1
- Document ID: US20160237420A1
- Status: Published application
- Kind: A1
- Application number: 15/136,810
- Filed: 2016-04-22
- Published: 2016-08-18
- Earliest claimed: 2014-08-20
- Assignees: Portola Pharmaceuticals, Inc.
- Inventors: Juan Wang; Gregory A. Sacha; Phuong M. Nguyen
- Web page: https://patentgrep.com/patent/US20160237420A1

## CPC

- C12N 9/6432: {Coagulation factor Xa (3.4.21.6)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C12Y 304/21006: Coagulation factor Xa (3.4.21.6)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.

## Claims

### Claim 1

An aqueous formulation, comprising from 10 mM to 55 mM arginine, from 1% to 3% sucrose (w/v), from 2% to 8% mannitol (w/v) and at least 5 mg/mL of a two-chain polypeptide comprising a first chain comprising the amino acid sequence of SEQ ID NO. 4, a second chain comprising the amino acid sequence of SEQ ID NO. 5, and a disulfide bond between a first Cysteine residue at position 98 (Cys98) of SEQ ID NO. 4 and a second Cysteine residue at position 108 (Cys108) of SEQ ID NO. 5, wherein the formulation has a pH from 7.5 to 8.

### Claim 2 (depends on 1)

The formulation of claim 1, comprising from 40 mM to 50 mM arginine, from 1.5% to 2.5% sucrose (w/v), from 4.5% to 5.5% mannitol (w/v) and at least 10 mg/mL of the polypeptide.

### Claim 3 (depends on 2)

The formulation of claim 2, comprising at least 18 mg/mL of the polypeptide.

### Claim 4 (depends on 2)

The formulation of claim 2, wherein the polypeptide comprises an amino acid residue that is modified to be different from natural amino acids.

### Claim 5 (depends on 4)

The formulation of claim 4, wherein residue Asp29 of the first chain is modified to (3R)-3-hydroxyAsp at Asp29.

### Claim 6 (depends on 1)

The formulation of claim 1, wherein the polypeptide comprises at least an intra-chain disulfide bond for each of the first and second chains.

### Claim 7 (depends on 1)

The formulation of claim 1, comprising at least about 10 mg/mL of the two-chain polypeptide.

### Claim 8 (depends on 1)

The formulation of claim 1, comprising at least about 20 mg/mL of the two-chain polypeptide.

### Claim 9

An aqueous formulation, comprising from 10 mM to 55 mM arginine, from 1% to 3% sucrose (w/v), from 2% to 8% mannitol (w/v) and at least 5 mg/mL of a two-chain polypeptide comprising a first chain comprising the amino acid sequence of SEQ ID NO. 4 or having at least 90% sequence identity to SEQ ID NO. 4, a second chain of the amino acid sequence of SEQ ID NO. 5 or having at least 90% sequence identity to SEQ ID NO. 5, and a disulfide bond between a first Cysteine residue at position 98 (Cys98) of SEQ ID NO. 4 and a second Cysteine residue at position 108 (Cys108) of SEQ ID NO. 5, wherein the formulation has a pH from 7.5 to 8.

### Claim 10 (depends on 9)

The formulation of claim 9, wherein the two-chain polypeptide has modifications to the Gla domain and the active site as compared to the wild-type fXa protein, is able to bind to a fXa inhibitor but does not assemble into a prothrombinase complex.

### Claim 11 (depends on 1)

A method of preparing a lyophilized formulation, comprising lyophilizing the aqueous formulation of claim 1.

### Claim 12 (depends on 1)

A lyophilized composition obtainable by lyophilizing the aqueous formulation of claim 1.

### Claim 13

A lyophilized composition comprising at least 10% (w/w) of a two-chain polypeptide comprising a first chain of the amino acid sequence of SEQ ID NO. 4, a second chain of the amino acid sequence of SEQ ID NO. 5, and a disulfide bond between a first Cysteine residue at position 98 (Cys98) of SEQ ID NO. 4 and a second Cysteine residue at position 108 (Cys108) of SEQ ID NO. 5, and L-arginine HCl:sucrose:mannitol in a weight ratio of the range (0.5-1.4):(1-3):(2-8).

### Claim 14 (depends on 13)

The lyophilized composition of claim 13, comprising at least 18% (w/w) of the two-chain polypeptide.

### Claim 15 (depends on 13)

The lyophilized composition of claim 13, wherein the weight ratio of L-arginine HCl:sucrose:mannitol is in the range of (0.9-1):(1.5-2.5):(4.5-5.5).

### Claim 16 (depends on 13)

The lyophilized composition of claim 13, wherein the weight ratio of L-arginine HCl:sucrose:mannitol is about 0.95:2:5.

### Claim 17 (depends on 13)

A method of reducing bleeding in a subject undergoing anticoagulant therapy with a factor Xa inhibitor comprising administering to the subject a solution prepared by dissolving the lyophilized composition of claim 13 in an aqueous solvent.

### Claim 18 (depends on 17)

The method of claim 17, wherein the factor Xa inhibitor is apixaban, rivaroxaban or betrixaban.

### Claim 19

An aqueous formulation, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO. 3 or an amino acid sequence having at least 95% sequence identity to SEQ ID NO. 3, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.

### Claim 20 (depends on 19)

The formulation of claim 19, wherein the crystalline component is mannitol present in a concentration from 2% to 8% (w/v), the solubilizing agent is arginine and the stabilizer is sucrose.

### Claim 21 (depends on 19)

The formulation of claim 19, further comprising a surfactant and a buffer.
